去纤维钠副作用及处理方法

Defibrotide is a single-chain sodium salt of polydeoxyribose ribonuclease that has antithrombotic, anti-ischemic, anti-inflammatory and profibrinolytic properties. In clinical practice, the drug is mainly used for the treatment of hepatic veno-occlusive disease (HVOD). Defibrotide is a polydisperse mixture of single-stranded oligonucleotides that can prevent endothelial cell damage without increasing the risk of systemic bleeding, and protect liver sinusoidal endothelial cells without weakening the anti-tumor effect of cytotoxic drugs. Defibrotide is not only used to prevent hepatic veno-occlusive disease (VOD), but can also be used to treat hepatic veno-occlusive disease (HVOD) and has good efficacy.

It has been reported abroad that the application of Defibrotide is effective in treating severe HVOD without significant toxicity. A foreign study first explored its application in the treatment of HVOD after HSCT. This study included 19 patients with sHVOD. The dosage of defibrotide is 5~60mg/kg per day, intravenous infusion, and the median usage time is 15d (2-61d). The results showed that 42% of patients achieved complete remission (CR), and the overall survival OS rate 100 days after transplantation was 32%, and Defibrotide was well tolerated by patients. Since then, multiple clinical trials have confirmed the effectiveness of defibrotide in the treatment of HVOD.

Treatment with Defibrotide will also produce certain side effects or adverse reactions. The most common side effects of this drug include: hypotension/diarrhea/vomiting/nausea/nose bleeding, etc. The incidence rate of grade 3-4 reactions related to defibrotide is 7%, mainly hypotension/pulmonary and gastrointestinal bleeding/abdominal cramps, etc. The side effects of Defibrotide are usually mild, and patients do not need to worry too much. Concomitant use of Defibrotide and a systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defibrotide treatment, and consider delaying initiation of defibrotide administration until the effects of the anticoagulant have lessened.

Since each patient's disease severity and circumstances are different, the form and severity of side effects also vary from person to person. If the patient's side effects are mild during treatment with Defibrotide, targeted treatment is not required. The symptoms will gradually disappear as the medication time increases. Once more serious side effects or intolerable side effects are discovered, you must seek medical treatment in time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: